BenevolentAI names industry vet Joerg Moeller as CEO

24 January 2024

AI specialist BenevolentAI (Euronext: BAI) today announced the appointment of Dr Joerg Moeller as chief executive and executive board member with immediate effect.

Dr Moeller brings a wealth of experience to BenevolentAI. During his career, he has led global research and development (R&D) organizations, successfully demonstrating innovation, commercial and operational excellence which resulted in long-term productivity and value creation. He initiated several drug discovery collaborations with artificial Intelligence (AI) platform companies and is a strong advocate of this strategy of accessing innovation.

Most recently, Dr Moeller served as executive vice president, head of global R&D at Denmark’s LEO Pharma. During his tenure, he re-organized and re-structured the global R&D organization to support growth and innovation ambitions of the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK